Teladoc Health, Inc. (NYSE:TDOC – Get Free Report) insider Carlos Nueno sold 29,432 shares of the business’s stock in a transaction dated Friday, November 6th. The shares were sold at an average price of $9.20, for a total value of $270,774.40. Following the completion of the transaction, the insider owned 35,312 shares in the company, valued at $324,870.40. This trade represents a 45.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Teladoc Health Trading Down 0.6%
Teladoc Health stock opened at $8.93 on Wednesday. Teladoc Health, Inc. has a twelve month low of $4.40 and a twelve month high of $9.89. The stock has a 50 day moving average of $6.61 and a two-hundred day moving average of $6.57. The stock has a market capitalization of $1.63 billion, a price-to-earnings ratio of -10.38 and a beta of 2.00.
Teladoc Health (NYSE:TDOC – Get Free Report) last announced its earnings results on Wednesday, October 28th. The health services provider reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.07. The company had revenue of $605.10 million for the quarter, compared to the consensus estimate of $588.14 million. Teladoc Health had a negative return on equity of 11.63% and a negative net margin of 6.27%. The company’s revenue was down 3.4% on a year-over-year basis. During the same period last year, the business posted ($0.28) EPS. Equities analysts predict that Teladoc Health, Inc. will post -0.86 earnings per share for the current year.
Hedge Funds Weigh In On Teladoc Health
Analyst Upgrades and Downgrades
A number of research firms recently weighed in on TDOC. Citigroup lowered their price objective on shares of Teladoc Health from $11.00 to $7.50 and set a “neutral” rating on the stock in a research report on Monday, August 3rd. Deutsche Bank Aktiengesellschaft raised their target price on shares of Teladoc Health from $10.00 to $11.00 and gave the stock a “buy” rating in a research note on Friday, October 30th. Oppenheimer lifted their target price on shares of Teladoc Health from $7.00 to $10.00 and gave the company an “outperform” rating in a report on Monday, November 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Teladoc Health in a report on Wednesday, August 19th. Finally, UBS Group boosted their price target on shares of Teladoc Health from $6.50 to $9.00 and gave the stock a “neutral” rating in a research note on Monday, November 2nd. Five equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Teladoc Health presently has an average rating of “Hold” and a consensus price target of $8.53.
Check Out Our Latest Analysis on TDOC
About Teladoc Health
Teladoc Health, Inc. provides virtual healthcare services through a digital platform that connects individuals with clinicians and other health professionals. Its offerings include virtual primary and specialty care, mental health services, and support for managing chronic conditions. The company serves members in the United States and internationally, with services and availability varying by market. Its consumer mental health services include BetterHelp, while its chronic-care programs draw on technology and services developed by Livongo, which Teladoc acquired in 2020.
Featured Articles
- Five stocks we like better than Teladoc Health
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.
